2024-24828. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List

Bulk drug substance	Uses evaluated
AOD-9604 (free base)	*Obesity.
AOD-9604 Acetate
CJC-1295 (free base)	Growth hormone deficiency.
CJC-1295 Acetate
CJC-1295 DAC (free base)
CJC-1295 DAC Acetate
CJC-1295 DAC Trifluoroacetate
Thymosin alpha-1(free base)	Hepatitis B.
Thymosin alpha-1 Acetate	Hepatitis C.
	Human immunodeficiency virus (HIV).
	Coronavirus disease 2019 (COVID-19).
	Depressed response to vaccinations; adjuvant to flu vaccines.
	Malignant melanoma.
	Hepatocellular carcinoma (HCC).
	Non-small cell lung cancer (NSCLC).
	Sepsis.
	Infections after hematopoietic stem cell transplantation (HSCT).
	Chronic obstructive pulmonary disease (COPD).
	Myalgic encephalomyelitis and chronic fatigue syndrome (ME/CFS).